Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.

Skin problems from transplant drugs are common and need careful management in organ transplant patients.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Tofacitinib helped regrow hair in a woman with alopecia areata.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.

Nilotinib can cause generalized keratosis pilaris.

Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.